Innovation1 Biotech Inc. (OTCMKTS:IVBT), announced on august 18, 2022, about filing a provisional patent application with the United States Patent and Trademark Office (USPTO) covering its novel and proprietary combination therapy targeting the addiction center in the human brain.
Trading Data
On Thursday, IVBT stock soared 27.52% to $0.3750 with more than 325 shares, compared to its average volume of 1K shares. The stock moved within a range of $0.3749 – 0.3750 after opening trade at $0.3749.
Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction
As opposed to traditional approaches to treat addiction, Innovation1’s combination therapy is aimed at restructuring neural networks to combat drug addiction by suppressing cravings and blocking withdrawal symptoms of opiates, alcohol, and nicotine.
The patent application uniquely combines therapeutics that target different aspects of the alpha3beta4 nicotinic acetylcholine receptor. The first component includes a prodrug of tetrahydrocannabivarin (THCV), modulating the level and desensitizing the expression of the alpha3beta4 nicotinic acetylcholine receptor. A second component, a synthetic analog of ibogaine designated 18-MAC, directly antagonizes the ligand binding to this receptor. Both components are manufactured chemically without any connection to the cannabis plant for THCV and tree bark of the iboga tree for 18-MAC, allowing for convenient and cost-effective sourcing.
Key Quote
“Addiction affects millions of people nationwide and remains a thriving epidemic across the U.S. between nicotine, alcohol, substance abuse, prescription, and illegal drugs,” said Dr. Andrew Salzman, Chief Science Officer of Innovation1 Biotech. “While each of these selected components have previously been utilized in experimental studies of addiction and drug withdrawal treatment, we believe this novel approach of combining the two will be much more effective in suppressing neuronal craving impulses. The two components each influence the alpha3beta4 nicotinic acetylcholine receptor, but do so in a different manner, thus making their combination profoundly impactful.”
Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors
On August 11, 2022, the company appointed its Chief Science Officer, Andrew L. Salzman, M.D., to the Board of Directors. He is a physician, scientist, inventor, and biomedical entrepreneur, with over three decades of experience in biomedical drug discovery and development. He has authored 175 peer-reviewed scientific publications and holds 60 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
